KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non&#8211;small-cell Lung Cancer by Renaud, S. et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:






(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/1719900 since 2019-12-21T15:07:51Z
Accepted Manuscript
KRAS-specific amino acid substitutions are associated with different responses to
chemotherapy in advanced non-small cell lung cancer
Stéphane Renaud, Francesco Guerrera, Joseph Seitlinger, Jérémie Reeb, Anne-
Claire Voegeli, Michèle Legrain, Bertrand Mennecier, Nicola Santelmo, Pierre-
Emmanuel Falcoz, Elisabeth Quoix, Marie-Pierre Chenard, Noëlle Weingertner,




To appear in: Clinical Lung Cancer
Received Date: 1 January 2018
Revised Date: 10 July 2018
Accepted Date: 11 August 2018
Please cite this article as: Renaud S, Guerrera F, Seitlinger J, Reeb J, Voegeli A-C, Legrain M,
Mennecier B, Santelmo N, Falcoz P-E, Quoix E, Chenard M-P, Weingertner N, Beau-Faller M, Massard
G, KRAS-specific amino acid substitutions are associated with different responses to chemotherapy in
advanced non-small cell lung cancer, Clinical Lung Cancer (2018), doi: 10.1016/j.cllc.2018.08.005.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all















KRAS-specific amino acid substitutions are associated with different responses to 
chemotherapy in advanced non-small cell lung cancer 
Stéphane Renaud1*, Francesco Guerrera2, Joseph Seitlinger3, Jérémie Reeb3, Anne-Claire 
Voegeli4, Michèle Legrain4, Bertrand Mennecier5, Nicola Santelmo3, Pierre-Emmanuel 
Falcoz3, Elisabeth Quoix5, Marie-Pierre Chenard6, Noëlle Weingertner6, Michèle Beau-
Faller4, Gilbert Massard3.  
1. Department of Thoracic Surgery. Nancy Regional University Hospital. Nancy. France 
2. Department of Thoracic Surgery, Azienda Ospedaliera Universitaria Città della Salute 
e della Scienza di Torino, Torino, Italy. 
3. Department of Thoracic Surgery. Strasbourg University Hospital. Strasbourg. France 
4. Department of Biochemistry and Molecular Biology. Strasbourg University Hospital. 
Strasbourg. France 
5. Department of Pneumology. Strasbourg University Hospital. Strasbourg. France 
6. Department of Pathology. Strasbourg University Hospital. Strasbourg. France 
*Corresponding author: Dr Stéphane Renaud, MD, PhD. Department of Thoracic Surgery. 
Nancy Regional University Hospital. Institut Lorrain du Coeur et des Vaisseaux Louis 
Mathieu. 5 Rue du Morvan. 54 500 Vandoeuvre-Lès-Nancy. E-mail: sterenaud0@gmail.com. 




















Background: Emerging data highlight different clinical behaviours according to KRAS amino 
acid substitutions (AASs) in non-small cell lung can er (NSCLC) patients. We aimed to 
evaluate whether different KRAS AASs were associated with different responses to 
chemotherapy. 
Methods: We retrospectively reviewed data from 1190 patients wi h KRAS mutations who 
underwent first-line platinum-based chemotherapy for stage IV NSCLC. The response to 
different chemotherapy regimens was evaluated using the RECIST criteria (v 1.1). Overall 
survival (OS) and time to progression (TTP) were secondary end points. 
Results: Taxane was associated with the best response in the entire cohort (OR: 2.52 (95% 
CI: 1.82-3.48), p<0.001), especially in G12V patients (OR: 2.15 (95% CI: 1.05-4.41), 
p=0.036). Taxane was associated with improved TTP in the entire cohort (HR: 0.31 (95% CI: 
0.26-0.38), p<0.001), especially in G13D patients (HR: 0.47 (95% CI: 0.22-1.01), p=0.054). 
Pemetrexed was associated with the worst TTP in the entire cohort, particularly in G12V 
patients, who had the worst response rates (HR: 0.55 (9 % CI: 0.30-0.99), p=0.049). No 
impact on OS was observed according to different chemotherapy regimens and AASs. 
Conclusion: KRAS-specific AAS appears to induce different responses to chemotherapy 
regimens after first-line platinum-based chemotherapy in advanced NSCLC.  
 


















Lung cancer remains the leading cause of cancer-related deaths worldwide 1. Non-small cell 
lung cancer (NSCLC) accounts for nearly 80% of histological subtypes. The last decade has 
seen a dramatically increased understanding of molecular alterations in cancer, helping 
clinicians offer a more accurate prognosis for patients and adapt therapies. Lung cancer, 
especially NSCLC, has not been left behind. Indeed, for some years now, we have witnessed 
the progressive evolution of a histological classification of NSCLC towards a molecular 
classification 2, 3. Especially in NSCLC adenocarcinomas, several oncogenic drivers have 
been discovered, and some have led to significant modifications in patients’ management and 
prognosis. Hence, activating mutations of exons 18-2  of the epidermal growth factor 
receptor (EGFR) or echinoderm microtubule-associated protein-like 4 (EML4) - anaplastic 
lymphoma kinase (ALK) translocation, conferring sensitivity to EGFR tyrosine kinase 
inhibitors (TKI) and ALK inhibitors, respectively, have been associated with significantly 
improved survival in metastatic NSCLC patients 4-6. 
Meanwhile, the prognostic and predictive values of these two mutations appear to be clearly 
established 7, 8, which is not the case for others, especially for V-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homologue (KRAS) mutations. Indeed, KRAS mutations are found in nearly 
30-35% of lung adenocarcinomas and are more frequent in smoking patients; these mutations 
mainly occur on exon 2 codon 12/13, have been considered as a single entity for many years 
and have mainly been linked to poor prognosis in NSCLC 9. However, recent data suggest 
that only a fleeting glimpse of KRAS mutations has thus far been explored 10. Indeed, in vitro 
and in vivo studies suggest there is important heterogeneity among KRAS mutations, 
especially according to amino acid substitutions. Hence, previous studies have shown that 















activated 11, leading to different clinical behaviours with a different prognosis 12, 13, different 
types of dissemination 14 or different responses to radiation therapy 15. 
More interestingly, based on an i vitro study demonstrating different sensitivities to 
chemotherapies 16, previous authors have attempted to investigate the different profiles of 
chemosensitivity according to KRAS amino acid substitution. However, despite interesting 
results, the current literature is poor, contradictory and mostly based on small retrospective 
cohorts 17-20. 
Consequently, we aimed to evaluate the response to different chemotherapy regimens 
according to KRAS amino acid substitution in a large cohort of metastatic NSCLC after first-



























This study was approved by the Ethics Committee of the French Society of Thoracic and 
Cardiovascular Surgeons (Approval Number: 2017-4-23-11-20-17-ReSt).  
We retrospectively reviewed data from patients suffering from NSCLC who underwent 
routine molecular testing for KRAS and EGFR between January 2007 and December 2015 at 
the molecular biology department of Strasbourg University Hospital (Strasbourg, France). 
Our study included stage IV NSCLC patients, according to the 7th TNM edition, with KRAS 
mutations who received platinum-based chemotherapy as a first-line treatment. Patients were 
excluded in cases of surgery, concurrent EGFR or ALK mutation, or the absence of 
documentation of response evaluation. Radiation therapy, as palliative treatment, was allowed 
during chemotherapy treatment. 
Molecular analysis 
Molecular analysis was performed at KRAS codons 12 and 13, as previously described 14. 
Samples for molecular analysis were obtained from pri ary or metastatic tumour sites. 
Covariate and data collection 
Baseline patient characteristics were collected, including age at diagnosis, sex, histology, 
chemotherapy combination, KRAS amino acid substitutions, smoking history and respon e to 
treatment. Smoking status was characterized as never a smoker, <100 cigarettes in their 
lifetime, a former smoker, quit >1 year before diagnosis and a current smoker with an 
ongoing smoking habit or who quit <1 year before diagnosis. The Charlson comorbidity index 
(CCI) was calculated for each patient. We grouped patients into the following established 
categories according to their total score 21: 0 (no comorbidity); 1–2 (average); 3–4 (moderate); 















1.1) 22. All baseline computed tomographic scans were reviewed by a dedicated radiologist 
who specialized in thoracic radiology during the multidisciplinary board. 
Statistical analysis 
Categorical data are presented as a number (percentage, %) and continuous data as the mean 
(standard deviation [SD]). 
Associations between the RECIST response and clinicopathological characteristics, 
chemotherapy regimens and KRAS mutations were investigated with the use of the logistic 
regression model. According to RECIST criteria, complete and partial responses were pooled 
into the response group (RG); meanwhile, stable and progressive diseases were pooled into 
the non-response group (NRG). 
The overall survival (OS) was defined as the time from the date of initiation of the first cycle 
of chemotherapy to the date of death from any cause. Patients still alive on the date of the last 
follow-up were censored. The time to progression (TTP) was defined as the time from the 
date of first treatment to the date of disease progression or death. Time-to-event variables 
were estimated using the Kaplan-Meier method and compared using a log-rank test. 
A Cox proportional hazard model was used to estimate the crude and adjusted hazard ratios 
(HRs) and 95% confidence intervals (CIs) as well as to evaluate possible predictors of the OS 
and TTP. The follow-up duration was used as the time scale. Predictors of the OS and TTP 
associated with P <0.2 on univariate analysis were included in the multivariable models. To 
limit the risk of α inflation, predictors identified in univariate analysis on the whole cohort 
were used in multivariate analysis for each subgroup analysis (i.e., pemetrexed, gemcitabine, 
taxane and bevacizumab groups). All tests were two-sided, and variables were considered 
significant for P-values <0.05. Statistical analyses were performed using Stata 13.1 

















According to the selection criteria, 1190 KRAS-mutated patients with Stage IV NSCLC who 
received platinum-based chemotherapy as first-line treatment were included in the analyses.  
The population demographics and clinical and pathologic characteristics of these patients are 
reported in Table 1.  
Most patients were male (756 – 63.5%) and active smokers (896 – 75.3%), and the mean age 
at the time of treatment was 67.2 years (SD ± 10.4). Adenocarcinoma was the most 
represented histology (1134 – 95.3%). All patients were dead or had experienced a disease 
progression at the date of last follow-up. 
Platinum-based chemotherapy was mostly associated wi h pemetrexed (476 – 40.0%), which 
was followed by vinorelbine (357 – 30%), taxane (238 – 20.0%) and gemcitabine (119 – 
10.0%). In the taxane group, 119 (50.0%) patients were treated with bevacizumab.  
Analyses of KRAS codon 12 mutations revealed 593 (49.8%) G12C, 240 ( 0.2%) G12V, 139 
(11.7%) G12D, 73 (6.1%) G12A, 27 G12S (2.3%), 15 G12R (1.3%), 11 G12F (0.9%) and 1 
G12L and G12N (0.1%). Because of their small proportion, G12F, G12L, G12N, G12R, 
G12S, and G12Y KRAS amino acid substitutions were included in “other G12” for further 
statistical analysis. Concerning codon 13, 48 (4.0%) KRAS G13C transversions and 38 


















RECIST response analysis 
Overall, at the end of follow-up period, a response to the treatments was observed in 345 
(29.0%) patients. 
The results of univariate and multivariate logistic regression analysis for the RECIST 
response are illustrated in Supplementary Table 1.  
In univariate analysis, the age (OR 0.97; P< 0.001; 95% CI 0.96-0.99) and male sex (OR 
0.49; P< 0.001; 95% CI 0.38-0.64) were found to be associated with the NRG. Chemotherapy 
regimens, including vinorelbine (OR 0.66; P= 0.01; 95% CI 0.47-0.91), were found to be 
associated with the NRG, while treatment with taxane (OR 2.52; P< 0.001; 95% CI 1.82-3.48) 
was associated with CR / PR. In the taxane group, bevacizumab administration (OR 2.91; P 
P< 0.001; 95% CI 1.72-4.92) was associated with the RG. The KRAS mutational status was 
not a significant predictor in univariate analysis of the whole cohort, while in patients treated 
with bevacizumab, only G12V mutations were associated with the RG (OR 3.37; P= 0.043; 
95% CI 1.04-11.0). 
In multivariate analysis, treatments with vinorelbine (OR 0.62; P= 0.01; 95% CI 0.44-0.87) 
and gemcitabine (OR 0.5; P= 0.01; 95% CI 0.30-0.83) were associated with NRG, while 
taxane regimen was associated with RG (OR 2.2; P< 0.001; 95% CI 1.56-3.10). KRAS 
mutational status was not a significant predictor in multivariate analysis of the whole cohort. 
In the taxane group (Table 2), bevacizumab administrat on (OR 3.42; P< 0.001; 95% CI 1.87-
6.27) was found to be independently associated withthe RG at the multivariate analysis. 
According to different chemotherapy regimens, G12V mutations were associated with the 
NRG in the pemetrexed group (OR 0.55; P= 0.049; 95%CI 0.30-0.99), while they were found 
to be associated with the RG in both the taxane (OR 2.15; P= 0.036; 95% CI 1.05-4.41) and 















Overall survival analysis 
Overall, the 6- and 12-month survival rates were 87% and 5%, respectively (Supplementary 
Figure 1). The results of the Cox models for the OS are illustrated in Table 3. 
In the univariate analysis, none of the variables of interest significantly influenced the OS. Of 
note, the KRAS mutational status was not a significant predictor of the OS on univariate 
analysis in the whole cohort or in patients treated with bevacizumab. 
When analysed according to different chemotherapy regimens (i.e., pemetrexed, vinorelbine, 
taxane, gemcitabine or bevacizumab), the OS was not significantly influenced by KRAS 
amino acid substitutions (data not shown). 
 
Time to progression analysis 
Overall, the 3-, 6- and 9-month TTP rates were 69%, 6% and 1%, respectively 
(Supplementary Figure 2). The results of univariate and multivariable Cox models for TTP 
are illustrated in Supplementary Table 2.  
In univariate analysis, the age (HR 1.02; P< 0.001; 95% CI 1.01-1.03) and male gender (HR 
1.34; P < 0.001; 95% CI 1.19-1.51) were found to have  negative effect on the TTP, while 
not otherwise specified (NOS) histology improved the TTP (HR 0.65; P= 0.004; 95% CI 
0.48-0.87). Chemotherapy regimens, including those with vinorelbine (HR 0.72; P< 0.001; 
95% CI 0.62-0.82), gemcitabine (HR 0.79; P= 0.02; 95% CI 0.64-0.96) and taxane (HR 0.29; 
P< 0.001; 95% CI 0.25-0.35), were associated with a better TTP (Figure 1). In the taxane 
group, bevacizumab administration was associated with a better TTP (HR 0.84; P= 0.009; 















In multivariate analysis (Supplementary Table 2), treatments with vinorelbine (HR 0.76; P< 
0.001; 95% CI 0.66-0.88) and taxane (HR 0.32; P< 0.001; 95% CI 0.26-0.38) were associated 
with a better TTP. KRAS mutational status was not a significant predictor in multivariate 
analysis of the whole cohort. However, G12D and G12V mutations tended to have a btter 
TTP, albeit not significantly (HR 0.85; P=0.08; 95% CI 0.70 - 1.02 and HR 0.86; P= 0.07; 
95% CI 0.74 - 1.01, respectively). 
In the sub-group multivariate analysis (Table 3), only G13D mutations tended to have a better 
TTP when submitted to taxane, albeit not significantly (OR 0.47; P= 0.054; 95% CI 0.22 - 
1.01). Finally, among patients treated with bevacizumab, all KRAS amino acid substitutions 

















In this large cohort study, we have shown that different types of KRAS amino acid 
substitutions may induce different responses to platinum-based chemotherapy regimens. 
Although KRAS mutations have been considered a unique entity for several decades, growing 
published evidence is highlighting the large heterog neity of KRAS mutations, leading to 
different clinical and molecular behaviours. In particular, previous authors have attempted to 
investigate different responses to chemotherapy according to amino acid substitution. 
Garassino et al. 16, in an in vitro model using NSCLC cell lines, were the first to objectivise 
different response sensitivity patterns. Indeed, G12C expression was associated with a 
reduced response to cisplatin and increased sensitivity to Taxol and pemetrexed; at the same 
time, the G12D mutant was associated with resistance to Taxol and sorafenib. Finally, G12V 
had high sensitivity to cisplatin with more resistance to pemetrexed. These different responses 
to chemotherapy regimens might be at least partially explained on a molecular basis by the 
different downstream signalling pathways activated according to amino acid substitution. 
Hence, in an in vitro study, Ihle et al. reported that both KRAS G12C and G12V exhibited 
activated Ral signalling and decreased growth factor-dependent Akt activation, although the 
G12D mutation exhibited activated PI3K and MEK signalli g 11. Based on these results, few 
retrospective clinical studies have been conducted without providing unequivocal 
conclusions. Jänne t al. 18, in a retrospective study based on 83 patients, report d that 
patients with KRAS G12C and G12V had better OS, progression-free survival (PFS) and 
objective response rate (ORR) than did patients with other KRAS mutations when treated with 
selumetinib plus docetaxel. In line with these results, Cserepes et al. 19, in a retrospective 
study based on 167 patients harbouring KRAS mutations, showed a better response to cisplatin 
in G12V patients. Mellema et al. 17, in a larger multi-centre cohort study in the Netherlands 















Metro et al. 20, in a retrospective cohort study based on 77 KRAS mutant patients, did not 
observe any difference according to amino acid substit tion. However, all were relatively 
small cohort studies, limiting their level of evidence.  
To the best of our knowledge, our study is thus far the largest published series on the impact 
of KRAS amino acid substitutions on the response to platinum-based chemotherapy regimens. 
In agreement with Garassino et al. 16, we have shown that G12V mutants were significantly 
more resistant to pemetrexed, with a lower ORR according to the RECIST criteria. 
Furthermore, pemetrexed was associated with a worse TTP than that of other chemotherapy 
regimens for all KRAS amino acid substitutions. Interestingly, in agreemnt with previous 
authors 16, 17, we have shown that taxane administration was related to an increased ORR in 
the whole cohort, especially in G12V patients, and  positive effect on TTP, especially in 
G13D patients, without impacting the OS. The explanatio  of this positive effect of taxane 
may rely on the interaction between microtubules and KRAS. Indeed, it has been previously 
noted that KRAS binds to microtubules with high affinity in a prenylation-dependent manner 
23. Hence, in cells treated with paclitaxel, cytoplasmic accumulation of KRAS was noted with 
reduced plasma membrane localization and redistribution into an endosomal compartment 24. 
Beyond its anti-mitotic activity, taxane may disturb KRAS intra-cellular trafficking, 
explaining the anti-proliferative activity observed with taxane. Interestingly, as noted by 
previous authors 17, 25, patients in our cohort treated with taxane + bevacizumab had a higher 
ORR than did those treated with taxane alone, especially in G12V patients. This effect may 
rely on the up-regulation of vascular endothelial growth factor (VEGF) production in KRAS-
mutated cancers, especially in codon 12 mutations 26-28. However, although bevacizumab 
administration was related to a better ORR, it was related to a significantly worse TTP in each 
subgroup of KRAS amino acid substitution in multivariate analysis. One can speculate on 















bevacizumab, by blocking VEGF production, induces a hypoxic microenvironment, with 
angiogenic escape in a hypoxia-inducible factor (HIF)-dependent manner, leading to tumour 
proliferation. Second, a “rebound effect” may occur at the time of bevacizumab 
discontinuation. Third, bevacizumab may interfere with other intra-cellular molecular 
pathways, especially microRNAs (miRNAs) 29, and induce a totally opposite effect. Indeed, 
miRNAs are known to act as double-edged swords, playing the role of both oncogenes and 
tumour-suppressor genes depending on the stimulus. For example, miR29b has been shown in 
KRAS G12V mutant NSCLC cell lines to tip the balance between apoptotic sensitization and 
resistance depending on extrinsic stimulation 30. However, these are only speculations, and 
further studies are necessary to elucidate these opposing effects of bevacizumab on KRAS 
mutants. 
Nonetheless, these observations suggest a large heterog neity of KRAS mutations. Hence, in 
the biology of KRAS-driven non-small cell lung cancer, in vitro studies have shown that two 
subgroups of KRAS mutated cells appear to exist. The first subgroup ap ears to depend on 
KRAS mutations for its survival, while the other does not 31. Consequently, directly targeting 
KRAS in the “KRAS-independent” group does not appear to be relevant because it does not 
affect cancer cell survival in vitro. However, the complexities of KRAS mutations are not 
limited here. Indeed, previous authors have also shown that 3 major subgroups of KRAS-
mutant NSCLC adenocarcinomas are defined by the co-xistence of other genetic alterations, 
STK11/LKB1, TP53 and CDKN2A/B 32. These different genetic alterations appear to be 
predictive of the response to anti-PD1/PDL1 immunotherapy in KRAS-mutated NSCLC 
because the immune tumour micro-environment appears to differ according to these co-
mutations 33, 34. In line with these observations, ALK translocation and KRAS mutations have 
thus far been considered mutually exclusive. However, r cent publications suggest a 















35, which may have biological and clinical consequences, such as different responses to 
treatment regimens, requiring further explorations in larger studies than those published thus 
far. 
Our study must be interpreted with caution based on a few limitations. First, it is a single-
centre, retrospective cohort study. For this reason, we were not able to collect data such as 
performance status (PS), presence of brain metastases and use of carboplatin vs cisplatin, or 
time of use of radiation therapy, which may have partially biased our results. However, even 
though CCI cannot totally replace PS, it has been sig ificantly associated in a recent work 
with survival after adjusting for PS in stage IIIB/IV NSCLC 36. Otherwise, although cisplatin 
has been associated with a slightly increased ORR, the 1-y survival does not differ between 
these two chemotherapy regimens 37. Because of the retrospective nature of our work, we did 
not have data from an EGFR/KRAS/ALK wild-type adenocarcinoma group for comparison. 
These data would be interesting in future studies to strengthen the results. Furthermore, 
except for G12C and G12V, the patient subgroups were r latively small. In particular, other 
G12 groups included various types of KRAS amino acid substitutions, preventing the 
exploration of all codon 12 biological effects. More ver, because none of the patients was 
treated with platinum alone, the impact of different AASs on sensitivity to platinum was not 
evaluated. Hence, one can speculate that part of differences observed between chemotherapy 
regimens can be related to different sensitivity to platinum according to the AAS. Finally, 
because our centre is a 3rd referral centre, patients are addressed by various oncologists. 
Consequently, the number of courses of the chemotherapy regimen may have been different 
among patients and may have led to a possible bias.  
In conclusion, this is the largest published series showing that KRAS amino acid substitutions 
may impact the response to chemotherapy. In particular, it appears that G12V patients are 















patients with KRAS mutations, especially G12V patients. Bevacizumab, lthough it is 
associated with a higher ORR, especially in G12V patients, appears to lead to a worse TTP. 
This opposite effect might require further investiga ons. Finally, as noted by previous 
authors, although ORR and TTP may differ according to the amino acid substitution and 
chemotherapy regimen, no impact on OS was noted [17, 19]. However, our study must be 
interpreted with caution based on its limitations. Prospective, multi-centre cohort studies are 
required to clearly elucidate the real impact of the eterogeneity of KRAS mutations. 
Nonetheless, these observations offer new hope to KRAS-mutant patients.  
 
Clinical Practice Points 
KRAS mutations, present in nearly 30-35% of lung adenocarcinomas and more frequent in 
smoking patients, have been considered as a single entity for many years and have been 
linked to poor prognosis in NSCLC. Current literatue, mostly based on small retrospective 
cohorts, is poor and contradictory about the different profiles of chemo-sensitivity according 
to KRAS amino acid substitution.  
Our study, performed on the largest published serie to date, demonstrated that different types 
of KRAS amino acid substitutions may induce different responses to platinum-based 
chemotherapy regimens. In particular, we showed that G12V mutants were significantly more 
resistant to pemetrexed. Furthermore, pemetrexed was associated with a worse TTP than that 
of other chemotherapy regimens for all KRAS amino acid substitutions. Finally, we observed 
that taxane administration was related to increased th rapy response outcomes in the whole 















In conclusion, our results suggest a large heterogeneity in profiles of chemo-sensitivity 
according to KRAS mutations. These observations offer new hope to KRAS-mutant patients 
and support the development of MEK inhibitors. 
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Figure 1: Kaplan-Meier representation of time to progression according to chemotherapy 
regimen in the whole cohort. 
Figure 2: Kaplan-Meier representation of time to progression according to bevacizumab use 
in the taxane group. 
Supplementary Figure 1: Kaplan-Meier representation of survival in the whole cohort. 


















Variable   N (%) G12A G12C G12D G12V Other G12* G13C G13D P 
Age at diagnosis (n= 1090) 0.46 
(years) (mean ± SD) 67.2 ± 10.4 67.1 ± 10.5 67.8 ± 10.3 66.7 ± 10.8 66.3 ± 10.6 66.8 ± 9.2 67.6 ± 10.1 65.7 ± 11.9  
Gender (n= 1090) 0.72 
Female 434 (36.5%) 27 (37.0%) 196 (33.1%) 57 (41.0%) 103 (42.9%) 22 (39%) 13 (27%) 16 (42%)  
Male 756 (63.5%) 46 (63.0%) 397 (66.9%) 82 (59.0%) 137 (57.1%) 34 (61%) 35 (73%) 22 (58%)  
Smoking history (n= 1190) 0.37 
Non-smoker 294 (24.7%) 15 (21.0%) 163 (27.5%) 29 (20.9%) 59 (24.6%) 15 (27%) 9 (19%) 4 (1.3%)  
Smoker 896 (75.3%) 58 (79.0%) 430 (72.5%) 110 (79.1%) 181 (75.4%) 41 (73%) 39 (81%) 37 (98.7)  
Histology (n= 1190) 0.45 
Adenocarcinoma 1134 (95.3%) 69 (95%) 567 (95.6%) 132 (95.0%) 230 (95.8%) 56 (100%) 43 (90%) 34 (89%)  
NOS° 46 (3.9%) 4 (5%) 20 (3.4%) 6 (4.3%) 8 (3.3%)  4 (8%) 4 (11%)  
Squamous cell carcinoma 10 (0.8%) 0 6 (1.0%) 1 (0.7%) 2 (0.8%)  1 (2%)   
KRAS mutations (n= 1190)  
G12A 73 (6.1%)         
G12C 593 (49.8%)         
G12D 139 (11.7%)         
G12F 11 (0.9%)     11 (20%)    
G12L 1 (0.1%)     1 (2%)    
G12N 1 (0.1%)     1 (2%)    
G12R 15 (1.3%)     15 (27%)    
G12S 27 (2.3%)     27 (48%)    
G12V 240 (20.2%)         
G12Y 1 (0.1%)     1 (2%)    
G13C 48 (4.0%)         
G13D 38 (3.2%)         
G13V 3 (0.3%)         
Charlson Comorbidity Index (n= 1190) 0.21 
0 136 (11.4%) 10 (14%) 85 (14.3%) 12 (8.6%) 23 (9.6%) 4 (7%) 2 (4%)   
1 341 (28.7%) 23 (32%) 155 (26.1%) 47 (33.8%) 80 (33.3%) 9 (16%) 20 (42%) 7 (18%)  
2 618 (51.9%) 34 (47%) 301 (50.8%) 71 (51.1%) 116 (48.3%) 40 (71%) 22 (46%) 31 (82%)  
3 95 (8.0%) 6 (8%) 52 (8.8%) 9 (6.5%) 21 (8.8%) 3 (5%) 4 (8%)   
Chemotherapy (n= 1190) 0.12 
Platinum + Pemetrexed 476 (40.0%) 25 (34%) 260 (43.8%) 44 (31.7%) 
87 (36.3%) 20 (36%) 25 (52%) 
15 (39%)  
Platinum + Vinorelbine 357 (30.0%) 29 (40%) 176 (29.7%) 45 (32.4%) 
53 (22.1%) 23 (41%) 13 (27%) 
15 (39%)  
Platinum + Taxane 238 (20.0%) 10 (14%) 98 (16.5%) 35 (25.2%) 
69 (28.7%) 10 (18%) 
8 (17%) 8 (21%)  
Platinum + Gemcitabine 119 (10.0%) 9 (12%) 59 (9.9%) 15 (10.8%) 
31 (12.9%) 3 (5%) 
2 (4%)   
Bevacizumab (Platinum + Taxane only) (n= 238) 0.17 
No 119 (50.0%) 6 (60%) 31 (32%) 22 (63%) 45 (65%) 7 (70%) 5 (63%) 5 (63%)  
Yes 119 (50.0%) 4 (40%) 67 (68%) 13 (37%) 24 (35%) 3 (30%) 3 (38%) 3 (38%)  
 

































































KRAS mutations         
  
G12C (reference)  (reference)  (reference)  (reference)  
(reference)  
G12A 0.39(0.13-1.20) 0.10 1.2(0.47-3.09) 0.70 0.59(0.066-5.36) 0.64 0.63(0.13-2.91) 0.55 
1.12(0.13-9.53) 0.92 
G12D 0.9(0.44-1.85) 0.78 1.15(0.52-2.55) 0.74 1.65(0.43-6.33) 0.47 1.42(0.53-3.78) 0.48 
1.57(0.39-6.31) 0.53 




Other G12 1.05(0.39-2.86) 0.92 1.4(0.51-3.84) 0.52 10.7(0.84-136.0) 0.07 0.4(0.073-2.16) 0.28 
2.86(0.20-40.6) 0.44 










G13V - - 2.64(0.23-30.5) 0.44 - - 0.99(0.95-1.03) 0.62 
1.12(0.13-9.53) 0.92 
Age at diagnosis (as continuous, 
years) 
        
  
 0.24(0.11-0.51) 0.0002 0.98(0.95-1.02) 0.31 0.99(0.93-1.05) 0.69   
1 (.)  
Gender 
        
  
Female 
(reference)  (reference)  (reference)  (reference)  
(reference)  














Bevacizumab (Taxane group 
only ; n=238) 
        
  
No -  -  -  (reference)  
  




CI: confidence interval °NOS: not otherwise specified; *Other G12 substitutions included G12F, G12L, G12N, G12R, G12S, and G12Y KRAS amino acid 
substitutions.  
^To limit the risk of α inflation, predictors associated with P <0.2 identified in the univariate analysis of the whole cohort were used in the multivariate 















Table 3: Univariate analysis of overall survival (OS) 
 
UNIVARIATE ANALYSIS 
Variable Hazard ratio 
(95% CI) 
P 
KRAS mutations  
 















Age at diagnosis 
(as continuous, years) 
  





Male 0.97(0.86-1.09) 0.61 
CCI (as continuous)   





Smoker 1.03(0.90-1.18) 0.64 
Histology 
  
Adenocarcinoma (reference)  
NOS 
1.02(0.76-1.37) 0.89 
Squamous cell carcinoma 
0.91(0.49-1.69) 0.76 
Chemotherapy   







Bevacizumab (Taxane group only)   















NOS: not otherwise specified. Other G12 substitutions included G12F, G12L, G12N, G12R, G12S, and 























































Variable             
KRAS mutations             
G12C (reference)  (reference)  (reference)  (reference)  (reference)  (reference)  
G12A 1.04(0.82-1.33) 0.74 1.16(0.77-1.75) 0.49 1.07(0.72-1.59) 0.74 0.73(0.35-1.50) 0.39 0.86(0.43-1.72) 0.66 7.15(2.31-22.1) <0.001 
G12D 0.96(0.80-1.16) 0.70 0.87(0.63-1.21) 0.42 0.94(0.67-1.31) 0.70 1.21(0.65-2.25) 0.54 0.8(0.48-1.31) 0.37 5.63(2.62-12.1) 
<0.000
1 
G12V 0.9(0.77-1.05) 0.18 0.92(0.72-1.17) 0.50 0.82(0.60-1.12) 0.20 0.95(0.60-1.50) 0.82 0.96(0.68-1.35) 0.8 3.43(2.03-5.82) 
<0.000
1 
Other G12 0.99(0.75-1.31) 0.97 1.18(0.74-1.87) 0.48 0.75(0.48-1.18) 0.21 0.86(0.27-2.80) 0.81 1.13(0.56-2.30) 0.73 9.82(2.60-37.0) 
<0.000
1 
G13C 1.03(0.77-1.39) 0.83 1.09(0.72-1.64) 0.70 1.06(0.59-1.88) 0.85 2.38(0.56-10.1) 0.24 0.73(0.33-1.59) 0.42 4.09(1.41-11.9) 0.01 
G13D 0.98(0.71-1.37) 0.92 1.1(0.60-1.99) 0.77 1.3(0.76-2.24) 0.34 - - 0.47(0.22-1.01) 0.054 4.53(1.37-15.0) 0.014 
G13V 0.64(0.20-1.98) 0.43 1.16(0.77-1.75) 0.49 0.54(0.17-1.70) 0.29 - - 0.86(0.43-1.72) 0.66 7.15(2.31-22.1) <0.001 
Age at diagnosis             














Gender             
Female (reference)  (reference)  (reference)  (reference)  (reference)  (reference)  
Male 1.34(1.19-1.51) <0.001 0.84(0.59-1.19) 0.33 1.46(0.98-2.20) 0.07 0.29(0.11-0.76) 0.012 0.85(0.47-1.54) 0.6 1.17(0.56-2.44) 0.68 
Smoking history             
Non-smoker (reference)  -  -  -  -    
Smoker 0.99(0.87-1.13) 0.86 -  -  -  -    
Histology             
Adenocarcinoma (reference)  (reference)  (reference)  (reference)  (reference)    
NOS 0.65(0.48-0.87) <0.001 0.96(0.45-2.05) 0.92 0.53(0.22-1.26) 0.15 5.95(1.50-23.6) 0.011 1.02(0.37-2.81) 0.97   
Squamous cell 
carcinoma 
1.12(0.60-2.09) 0.72 0.78(0.18-3.36) 0.74 - - 5.89(1.06-32.9) 0.043 - - 
  
Chemotherapy             
Pemetrexed (reference)            
Vinorelbine 0.72(0.62-0.82) <0.001 -  -  -  -    
Taxane 0.29(0.25-0.35) <0.001 -  -  -  -    
Gemcitabine 0.79(0.64-0.96) 0.02 -  -  -  -    
Bevacizumab 
(Taxane group only) 
          
  
No (reference)  -  -  -  (reference)    













NOS: not otherwise specified; Other substitutions G12 included G12F, G12L, G12N, G12R, G12S, and G12Y KRAS amino acid substitutions. To limit the risk of 
α inflation, predictors identified in univariate analysis on the whole cohort were used in multivariate analysis for each subgroup analysis (i.e., pemetrexed, 





































































Suplementary Table 1: Univariate and multivariate analyses of response to chemotherapy according to the RECIST criteria 
 
UNIVARIATE ANALYSIS 
MULTIVARIATE ANALYSIS  
(n= 1090) 
Variable 
Hazard ratio (95% CI) P Hazard ratio (95% CI) P 
KRAS mutations  
 
  
G12C (reference)  (reference)  
G12A 
0.64(0.35-1.17) 0.15 0.68(0.37-1.25) 0.21 
G12D 
1.19(0.80-1.77) 0.39 1.1(0.73-1.66) 0.66 
G12V 
1.07(0.77-1.48) 0.70 0.88(0.62-1.24) 0.46 
Other G12 
1.08(0.60-1.97) 0.79 1.06(0.57-1.97) 0.86 
G13C 
0.92(0.48-1.79) 0.82 0.92(0.47-1.82) 0.82 
G13D 
1.15(0.57-2.33) 0.70 1(0.47-2.10) 0.99 
G13V 
1.24(0.11-13.8) 0.86 2.53(0.22-28.5) 0.45 
Age at diagnosis 
(as continuous, years) 





    
Female 
(reference)  (reference)  
Male 0.49(0.38-0.64) <0.001 0.5(0.34-0.74) <0.001 
Smoking history 
    
Non-smoker 
(reference)    
Smoker 1.01(0.75-1.34) 0.97 
-  
Histology 
    




Squamous cell carcinoma 1 (.)  -  
Chemotherapy     










Bevacizumab (Taxane group only ; n=238)     
No (reference)    
Yes 
2.91(1.72-4.92) 
<0.001 -  
CI: confidence interval °NOS: not otherwise specified; *Other G12 substitutions included G12F, 






























Supplementary Table 2: Univariate and multivariate analyses on the time to progression (TTP) 
 UNIVARIATE 
ANALYSIS 
MULTIVARIATE ANALYSIS  
(n=1090) 
 Hazard ratio 
(95% CI) 
P 
Adjusted hazard ratio 
(95% CI) 
P 
Variable     
KRAS mutations     
G12C (reference)    
G12A 1.04(0.82-1.33) 0.74 0.87(0.68 - 1.11) 0.25 
G12D 0.96(0.80-1.16) 0.70 0.85(0.70 - 1.02) 0.08 
G12V 0.9(0.77-1.05) 0.18 0.86(0.74 - 1.01) 0.07 
Other G12 0.99(0.75-1.31) 0.97 0.85(0.64 - 1.12) 0.25 
G13C 1.03(0.77-1.39) 0.83 0.86(0.64 - 1.16) 0.31 
G13D 0.98(0.71-1.37) 0.92 0.98(0.70 - 1.37) 0.9 
G13V 0.64(0.20-1.98) 0.43 0.44(0.14 - 1.39) 0.16 
Age at diagnosis     
(as continuous, years) 1.02(1.01-1.03) <0.001 1.01(1.00 - 1.02) 0.08 
Gender     
Female (reference)    
Male 1.34(1.19-1.51) <0.001 1.03(0.84 - 1.27) 0.77 
Smoking history     
Non-smoker (reference)    
Smoker 0.99(0.87-1.13) 0.86   
Histology     
Adenocarcinoma (reference)    
NOS 0.65(0.48-0.87) <0.001 0.92(0.62 - 1.38) 0.7 
Squamous cell carcinoma 1.12(0.60-2.09) 0.72 1.04(0.51- 2.12) 0.92 
Chemotherapy     
Pemetrexed (reference)    
Vinorelbine 0.72(0.62-0.82) <0.001 0.76(0.66 - 0.88) <0.001 
Taxane 0.29(0.25-0.35) <0.001 0.31(0.26 - 0.38) <0.001 
Gemcitabine 0.79(0.64-0.96) 0.02 0.89(0.72 - 1.11) 0.31 
Bevacizumab (Taxane group only)     
No (reference)    
Yes 0.63(0.49-0.82) <0.001 -  
CI: confidence interval °NOS: not otherwise specified; *Other G12 substitutions included G12F, 
















<0.2 identified in the univariate analysis were used in the multivariate analysis.  CI: confidence 
interval °NOS: not otherwise specified; *Other G12 substitutions included G12F, G12L, G12N, G12R, 
G12S, and G12Y KRAS amino acid
